Here you will find all our clinical education resources from articles to recorded webinars, all supporting equitable access to funded medicines.
This recorded webinar covers the introduction of the adalimumab biosimilar Amgevita in New Zealand, and what it means for primary care. Specialist Dr David Liew shares his experiences of changing patients from biologics to biosimilars in Australia, and Andrea Copeland provides some local context.
In this article, Dr Jim Vause contemplates managing CVD risk, reasons for non-adherence, inequities in CVD treatment, and how to improve communication with patients.
Adalimumab is used to treat a range of dermatological, rheumatological, gastrointestinal and ophthalmologic conditions. From 1 March, Amgevita (an adalimumab biosimilar) is funded under Special Authority. From this date, patients starting treatment with adalimumab will receive Amgevita rather than the reference product, Humira.
In this recorded webinar, Professor Lisa Stamp explores the management of gout as a long-term condition and challenges old beliefs. Dr Noni Richards introduces the EPiC Gout dashboard and outlines how it can be used to highlight and address inequities.
Looking for up-to-date information on biological medicines? You can find it here!
We’ve linked resources from multiple providers into one place so it’s easy for you to find what you need.
This article summarises the 2022 changes regarding adalimumab funding and access in New Zealand. It also provides some background and resources to foster confidence in biosimilars, and references real-world data from studies of patients changing from Humira to Amgevita.
Cardiovascular disease is the leading cause of death in New Zealand, accounting for 35 per cent of mortality in 2019. Yet it’s preventable and treatable. Māori, Pacific, and South Asian peoples have a disproportionately higher CVD risk compared with people not of these ethnicities. Therefore, CVD risk assessments in these ethnicities should begin earlier.
This video demonstrates how the three-step Ask, Build, Check health literacy model can be incorporated into discussions about the long-term management of gout, to help improve patient outcomes.
Please note that this is the video version of the Legendary Conversations podcast Episode Four: Let's talk gout (part 2).
This podcast demonstrates how the three-step Ask, Build, Check health literacy model can be incorporated into discussions about the long-term management of gout, to help improve patient outcomes.
Please note that this is the podcast version of the video Let's talk gout.
Prescribers are instrumental in framing a medicine positively or negatively, setting patient expectations. Optimising these expectations during a short consult can enhance and sustain benefits. Conversely, highlighting negative information may lead to increased experience, and reporting, of adverse events, and to poor adherence.
Episode three of our Legendary Conversations podcast is out now! Listen to three experts as they discuss attitudes towards gout and how to better communicate with patients to improve gout outcomes.
Rosuvastatin is now fully funded on Special Authority for people at increased risk of cardiovascular complications due to high cholesterol, and may be considered first-line for Māori and Pacific peoples.
An abridged version of this article, containing the eligibility flowchart, is available for printing - see the link in the contents box.